Evaluating ER-100 for Safety in People With Glaucoma or Non-Arteritic Anterior Ischemic Optic Neuropathy (Optic Nerve Conditions)

Recruiting

Phase 1

ER-100Evaluating ER-100 for Safety in People With Glaucoma or Non-Arteritic Anterior Ischemic Optic Neuropathy (Optic Nerve Conditions)

Sponsor:

Life Biosciences Inc.

Code:

NCT07290244

Conditions

Open Angle Glaucoma (OAG)

NAION( Non-arteritic Anterior Ischemic Optic Neuropathy)

Eligibility Criteria

Sex: All

Age: 40 - 70+

Healthy Volunteers: Not accepted

Interventions

ER-100 epigenetic therapy

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-03-10. This information was provided to ClinicalTrials.gov by Life Biosciences Inc. on 2026-03-09.